An FDA panel recommended approval of a marijuana-derived medicine for the treatment of severe seizures in children with epilepsy; prescriptions for opioid painkillers continued to fall while the number of new monthly prescriptions for medications that treat opioid use disorder nearly doubled over the past 2 years; GOP candidates in midterm races this fall are retreating from calls to further dismantle the Affordable Care Act.
An FDA panel recommended approval of a marijuana-derived medicine for the treatment of severe seizures in children with epilepsy, the Associated Press reported. If the FDA follows the panel’s recommendation, GW Pharmaceuticals’ syrup, called Epidiolex, would become the first drug made from cannabis to win federal approval. A decision is expected in June. The panel’s decision was based on 3 studies showing the drug significantly reduced seizures in children with 2 rare forms of childhood epilepsy.
Prescriptions for opioid painkillers continued to fall while the number of new monthly prescriptions for medications that treat opioid use disorder nearly doubled over the past 2 years, The New York Times reported. Prescriptions for opioid painkillers have been dropping since 2011, but the trend sped up last year with a decline of 10%, according to the IQVIA Institute for Human Data Science. The changes reflect new efforts among policy makers, lawmakers, and the medical community; although, there are concerns about whether some pain patients are now being undertreated, and whether tightened prescribing has contributed to the surge in overdose deaths from heroin and especially fentanyl.
With Democrats surging ahead on the healthcare issue, GOP candidates in midterm races this fall are retreating from calls to further dismantle the Affordable Care Act, The Hill reported. Democrats are going on the offense, attacking Republicans for their past votes as they hope to retake the House majority less than a year after the GOP gave up on its legislative effort to repeal the law.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen